Dr. Levitsky: My organization within Roche, Pharma Research and Early Development (pRED), has invested in antibody engineering, not only for use of monoclonal antibodies in the established ways of delivering cell - killing agents to tumors or
interrupting cell signalling pathways, but also as ways to engage and manipulate the immune system's response to tumors.